Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Alexandru Odainic, Ioannis Vardaxis, Matheus Ferraz, Katrin E. Wiese, Lisette A. H. M. Cornelissen, Akhilesh Sharma, Richard Stratford, Trevor Clancy, Kaïdre Bendjama
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
openalex
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
The molecular epidemiology of multiple zoonotic origins of SARS-CoV-2
10.1126/science.abp8337 · 2022
The origins of SARS-CoV-2: A critical review
10.1016/j.cell.2021.08.017 · 2021
Developing safe and effective Covid vaccines — Operation Warp Speed’s strategy and approach
10.1056/nejmp2027405 · 2020
Warp Speed” operations in the COVID-19 pandemic
10.1016/j.jacbts.2020.06.001 · 2020
mRNA and adenoviral vector vaccine platforms utilized in COVID-19 vaccines: Technologies, ecosystem, and future directions
10.3390/vaccines11121737 · 2023
COVID-19 mRNA vaccines: Platforms and current developments
10.1016/j.ymthe.2022.02.016 · 2022
Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
10.1056/nejmoa2034577 · 2020
Challenges to the effectiveness and immunogenicity of COVID-19 vaccines: A narrative review with a systematic approach
10.3390/vaccines13080789 · 2025
Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population
10.1038/s41591-023-02219-5 · 2023
Immune evasion of SARS-CoV-2 variants of concern is driven by low affinity to neutralizing antibodies
10.1039/d1cc01747k · 2021
SARS-CoV-2 variants, spike mutations and immune escape
10.1038/s41579-021-00573-0 · 2021
Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology
10.1016/j.cell.2020.09.037 · 2020
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
10.1038/s41586-021-04385-3 · 2022
Comparative analysis of antibody titers against the spike protein of SARS-CoV-2 variants in infected patient cohorts and diverse vaccination regimes
10.3390/ijms232012231 · 2022
The Batalogue: An overview of betacoronaviruses with future pandemic potential
10.1093/femsre/fuaf023 · 2025
Origin and evolution of pathogenic coronaviruses
10.1038/s41579-018-0118-9 · 2019
Beyond the pandemic era: Recent advances and efficacy of SARS-CoV-2 vaccines against emerging variants of concern
10.3390/vaccines13040424 · 2025
Effect of antigenic drift on influenza vaccine effectiveness in the United States—2019–2020
10.1093/cid/ciaa1884 · 2021
Influenza vaccine strain selection with an AI-based evolutionary and antigenicity model
10.1038/s41591-025-03917-y · 2025
Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: Phase 2/3 trial interim results
10.1038/s41591-023-02517-y · 2023
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice
10.1038/s41591-022-02092-8 · 2023
Broad-spectrum Delta-BA. 2 tandem-fused heterodimer mRNA vaccine delivered by lipopolyplex
10.1371/journal.ppat.1012116 · 2024
Toward a pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses
10.1371/journal.ppat.1010870 · 2023
Broad-spectrum coronavirus vaccines: Integrated strategies to combat viral diversity
10.1080/14760584.2025.2538561 · 2025
SARS-CoV-2 pandemic: Not the first, not the last
10.3390/microorganisms9020433 · 2021
Emerging pandemic diseases: How we got to COVID-19
10.1016/j.cell.2020.08.021 · 2020
Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting
10.1016/j.celrep.2022.110561 · 2022
Pan-variant SARS-CoV-2 vaccines induce protective immunity by targeting conserved epitopes
10.1002/advs.202409919 · 2025
Deep learning of antibody epitopes using positional permutation vectors
10.1016/j.csbj.2024.06.005 · 2024
Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models
10.1126/science.abq0839 · 2022
Designed mosaic nanoparticles enhance cross-reactive immune responses in mice
10.1016/j.cell.2024.12.015 · 2025
Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals
10.1016/j.cell.2024.07.052 · 2024
A spike virosome vaccine induces pan-sarbecovirus antibody responses in mice
10.1016/j.isci.2024.109719 · 2024
Proactive vaccination using multiviral Quartet Nanocages to elicit broad anti-coronavirus responses
10.1038/s41565-024-01655-9 · 2024
Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice
10.1126/science.abi4506 · 2021
Broad-spectrum vaccines against various and evolving viruses: From antigen design to nanoparticle delivery
10.1128/jvi.00997-25 · 2025
Chimeric hemagglutinin split vaccines elicit broadly cross-reactive antibodies and protection against group 2 influenza viruses in mice
10.1126/sciadv.adi4753 · 2023
Rational design of an influenza-COVID-19 chimeric protective vaccine with HA-stalk and S-RBD
10.1080/22221751.2023.2231573 · 2023
Multivalent mRNA vaccine elicits broad protection against SARS-CoV-2 variants of concern
10.3390/vaccines12070714 · 2024
Immune imprinting: The persisting influence of the first antigenic encounter with rapidly evolving viruses
10.1016/j.celrep.2020.108666 · 2024
Accurate calculation of hydration free energies using macroscopic solvent models
10.1021/j100058a043 · doi-reference
PDB2PQR: an automated pipeline for the setup of Poisson–Boltzmann electrostatics calculations
10.1093/nar/gkh381 · doi-reference
Improvements to the APBS biomolecular solvation software suite
10.1002/pro.3280 · doi-reference
Perturbation-response scanning reveals ligand entry-exit mechanisms of ferric binding protein
10.1371/journal.pcbi.1000544 · doi-reference
ATPase subdomain IA is a mediator of interdomain allostery in hsp70 molecular chaperones
10.1371/journal.pcbi.1003624 · doi-reference
Anisotropic network model: systematic evaluation and a new web interface
10.1093/bioinformatics/btl448 · doi-reference
Anisotropy of fluctuation dynamics of proteins with an elastic network model
10.1016/s0006-3495(01)76033-x · doi-reference
Shared signature dynamics tempered by local fluctuations enables fold adaptability and specificity
10.1093/molbev/msz102 · doi-reference
ProDy: protein dynamics inferred from theory and experiments
10.1093/bioinformatics/btr168 · doi-reference
LINCS: A linear constraint solver for molecular simulations
10.1002/(sici)1096-987x(199709)18:12<1463::aid-jcc4>3.0.co;2-h · doi-reference
Polymorphic transitions in single crystals: A new molecular dynamics method
10.1063/1.328693 · doi-reference
Crystal structure and pair potentials: A molecular-dynamics study
10.1103/physrevlett.45.1196 · doi-reference
Particle mesh Ewald: An N·log(N) method for Ewald sums in large systems
10.1063/1.464397 · doi-reference
Comparison of simple potential functions for simulating liquid water
10.1063/1.445869 · doi-reference
GLYCAM06: A generalizable biomolecular force field. Carbohydrates
10.1002/jcc.20820 · doi-reference
ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB
10.1021/acs.jctc.5b00255 · doi-reference
GROMACS: Fast, flexible, and free
10.1002/jcc.20291 · doi-reference
Vulnerabilities in coronavirus glycan shields despite extensive glycosylation
10.1038/s41467-020-16567-0 · doi-reference
PROPKA3: consistent treatment of internal and surface residues in empirical p K a predictions
10.1021/ct100578z · doi-reference
Potent cross-reactive antibodies following Omicron breakthrough in vaccinees
10.1016/j.cell.2022.05.014 · doi-reference
Relaxation of backbone bond geometry improves protein energy landscape modeling
10.1002/pro.2389 · doi-reference
A Pareto-optimal refinement method for protein design scaffolds
10.1371/journal.pone.0059004 · doi-reference
Simultaneous optimization of biomolecular energy functions on features from small molecules and macromolecules
10.1021/acs.jctc.6b00819 · doi-reference
The Rosetta all-atom energy function for macromolecular modeling and design
10.1021/acs.jctc.7b00125 · doi-reference
Comprehensive assessment of protein loop modeling programs on large-scale datasets: prediction accuracy and efficiency
10.1093/bib/bbad486 · doi-reference
Sub-angstrom accuracy in protein loop reconstruction by robotics-inspired conformational sampling
10.1038/nmeth0809-551 · doi-reference
Structural and functional characteristics of the SARS-CoV-2 Omicron subvariant BA.2 spike protein
10.1038/s41594-023-01023-6 · doi-reference
Protein Data Bank: the single global archive for 3D macromolecular structure data
10.1093/nar/gky949 · doi-reference
Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
10.1126/science.abo2523 · doi-reference
Evidence for antibody as a protective correlate for COVID-19 vaccines
10.1016/j.vaccine.2021.05.063 · doi-reference
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
10.1038/s41591-021-01377-8 · doi-reference
Insufficient anti-spike RBD IgA responses after triple vaccination with intramuscular mRNA BNT162b2 vaccine against SARS-CoV-2
10.1016/j.heliyon.2023.e23595 · doi-reference
SARS-CoV-2 XBB.1.5 mRNA booster vaccination elicits limited mucosal immunity
10.1126/scitranslmed.adp8920 · doi-reference
Understanding the implications of delaying seasonal influenza vaccine recommendations: An industry perspective
10.3390/vaccines13090891 · doi-reference
Conformational dynamics and allosteric modulation of the SARS-CoV-2 spike
10.7554/elife.75433 · doi-reference
Controlling the SARS-CoV-2 spike glycoprotein conformation
10.1038/s41594-020-0479-4 · doi-reference
Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein
10.1016/j.cell.2020.02.058 · doi-reference
De novo protein design enables the precise induction of RSV-neutralizing antibodies
10.1126/science.aay5051 · doi-reference
Computationally designed Spike antigens induce neutralising responses against the breadth of SARS-CoV-2 variants
10.1038/s41541-024-00950-9 · doi-reference
The immunodominant and neutralization linear epitopes for SARS-CoV-2
10.1101/2020.08.27.267716 · doi-reference